1. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma;Finn;N Engl J Med,2020
2. IMbrave150: updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC);Finn;J Clin Oncol,2021
3. Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma;Flecken;Hepatology,2014
4. Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features;Sia;Gastroenterology,2017
5. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial;Finn;J Clin Oncol,2020